| Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. | |
| | |
MedLine Citation:
|
PMID: 1346819 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Antiphospholipid antibodies have been suggested as markers for a high risk of recurrent cardiovascular events in young survivors of an acute myocardial infarction. However, there are few data to confirm or refute this hypothesis. In a cohort study, we have measured anticephalin (aCEPHA) and anticardiolipin (aCL) antibodies in a group of patients surviving an acute infarct. Of 597 patients studied, 13.2% were IgG or IgM aCEPHA positive compared with 4.4% of a reference population (n = 158; p = 0.002). In a multivariate analysis, adjusted for major cardiovascular risk factors, neither aCEPHA (IgG or IgM) nor a CL (IgG or IgM) was an independent risk factor for mortality, reinfarction, or non-haemorrhagic stroke. Although an increased proportion of survivors of a myocardial infarction have antiphospholipid antibodies, the presence of such antibodies is not a risk factor for subsequent coronary or cerebrovascular thrombosis. |
| | |
Authors:
|
K E Sletnes; P Smith; M Abdelnoor; H Arnesen; F Wisløff |
Related Documents
:
|
17119879 - A direct assessment of genetic contribution to the incidence of coronary infarct in the... 21656649 - Left main coronary artery stenting after cardiac arrest in an infant with william's syn... 19126929 - Acute myocardial infarction in two young women without significant risk factors. 21563299 - Defective sumoylation pathway directs congenital heart disease. 15232399 - Occupational magnetic field exposure and myocardial infarction incidence. 12426569 - Functional snps in the lymphotoxin-alpha gene that are associated with susceptibility t... 23438549 - Mitral annulus reconstruction and giant left atrial reduction plasty. 22187199 - Myocardial perfusion abnormality in the area of ventricular septum-free wall junction a... 15877999 - Effect of nifedipine on c-reactive protein levels in the coronary sinus and on coronary... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Lancet Volume: 339 ISSN: 0140-6736 ISO Abbreviation: Lancet Publication Date: 1992 Feb |
Date Detail:
|
Created Date: 1992-03-20 Completed Date: 1992-03-20 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 2985213R Medline TA: Lancet Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 451-3 Citation Subset: AIM; IM |
Affiliation:
|
Haematological Research Laboratory, Ullevål University Hospital, Oslo, Norway. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Autoantibodies / analysis, immunology* Biological Markers Cardiolipins / immunology Cerebrovascular Disorders / etiology Enzyme-Linked Immunosorbent Assay Female Humans Immunoglobulin G / analysis Immunoglobulin M / analysis Intracranial Embolism and Thrombosis / etiology Male Middle Aged Myocardial Infarction / immunology*, mortality Phospholipids / analysis, immunology* Prognosis Recurrence Risk Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Autoantibodies; 0/Biological Markers; 0/Cardiolipins; 0/Immunoglobulin G; 0/Immunoglobulin M; 0/Phospholipids |
| Comments/Corrections | |
Comment In:
|
Lancet. 1992 Apr 11;339(8798):929-30
[PMID:
1348318
]
Lancet. 1992 Jul 11;340(8811):117-8 [PMID: 1351986 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary...
Next Document: Stridor and focal laryngeal dystonia.